$1250 | Single User
$1800 | Site License
$2500 | Global License

Cannabinoids (CBD and THC) Drugs: Pipeline Analysis and Opportunity Assessment, H1 2020
[Lowest Price Guaranteed: $1,250]

Published by Gervano R A: 26 Jan 2019 | 270543 | In Stock
Related Topics: Clinical Trials , Drug

Introduction

GervanoRA's pipeline analysis and opportunity assessment report "Cannabidiol (CBD) Drugs: Pipeline Analysis and Opportunity Assessment, H2 2020" analyzed and assessed Cannabidiol pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Cannabidiol Drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Molecules by Geography, Pipeline Molecules by Drug Class, Pipeline Molecules by Mechanism of Action and Pipeline Molecules by Stage of development.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

• Unmet needs and Opportunities

• Epidemiology and Epidemiology forecast 2019 - 2025

• Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)

• Patent Analysis of Pipeline Molecules

• Pipeline Analysis and Estimated Pipeline Drug Approval Time lines

• Clinical Trials Summary

• Current and Future Competitive Landscape

• Key Company Profiles with SWOT Analysis

• Emerging Company Profiles with Opportunity Assessments

• Pipeline Drug Descriptions along with Development milestones (Past and Future)

• University Pipeline Molecules & In-Licensing/Out Licensing Opportunities

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

Table of Contents
for Cannabinoids (CBD and THC) Drugs: Pipeline Analysis and Opportunity Assessment, H1 2020

  • TABLE OF CONTENTS

    1. INTRODUCTION

    1.1. REPORT DESCRIPTION

    1.2. METHODOLOGY

    1.3. UPCOMING AND OTHER AVAILABLE PIPELINE ANALYSIS REPORTS

    1.4. ABOUT US: GERVANORA DATA SERVICES

    2. EXECUTIVE SUMMARY

    2.1. REPORT SUMMARY

    2.2. KEY EVENTS IN CANNABINOIDS COMPETITIVE SPACE

    2.3. KEY MAJOR FINDINGS

    2.3.1. DRIVERS

    2.3.2. RESTRAINTS

    2.3.3. UNMET NEEDS AND OPPORTUNITIES

    3. CANNABINOIDS DRUGS OVERVIEW

    3.1. CANNABIS OUTLOOK

    3.2. GLOBAL CANNABIS PRODUCT OUTLINE

    4. MARKET DYNAMICS

    4.1. GOVERNMENT REGULATORY DYNAMICS AND IMPACT

    4.2. DEALS (MERGERS/ ACQUISITIONS / COLLABORATIONS)

    4.2.1. ACQUISITIONS

    4.2.2. COLLABORATION AGREEMENTS

    4.2.3. LICENSING AGREEMENTS

    4.2.4. TERMINATION AGREEMENTS AND SETTLEMENTS

    4.2.5. PARTNERSHIPS

    4.2.6. AGREEMENTS

    4.3. NEW DRUG APPROVALS (EMA)

    4.4. NEW DRUG APPROVALS (USFDA)

    4.5. PATENT ANALYSIS (EXPIRES AND GENERICIZATION)

    5. PIPELINE ANALYSIS AND ESTIMATED APPROVAL TIMELINE

    5.1. PIPELINE ANALYSIS BY STAGE OF DEVELOPMENT

    5.1.1. PRE-REGISTRATION (FILED) MOLECULES

    5.1.2. PHASE 3 MOLECULES

    5.1.3. PHASE 2 MOLECULES

    5.1.4. PHASE 1 MOLECULES

    5.1.5. PRECLINICAL MOLECULES

    5.1.6. EARLY R&D MOLECULES

    5.1.7. HSD-UNKNOWN

    5.2. PIPELINE ANALYSIS BY GEOGRAPHY

    5.2.1. UNMET NEEDS AND OPPORTUNITIES

    5.3. PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION

    5.3.1. UNMET NEEDS AND OPPORTUNITIES

    5.4. PIPELINE ANALYSIS BY DRUG CLASS

    5.4.1. UNMET NEEDS AND OPPORTUNITIES

    5.5. PIPELINE ANALYSIS BY MECHANISM OF ACTION

    5.6. PIPELINE ANALYSIS BY INDICATION

    5.6.1. UNMET NEEDS AND OPPORTUNITIES

    5.7. ANALYTICS ON PIPELINE MOLECULES BY SOURCE OF ORIGIN (PLANT DERIVED VERSUS SYNTHETIC ANALYTICS)

    5.8. ANALYTICS ON PIPELINE MOLECULES BY TYPE (CANNABIDIOL - CBD VS TETRAHYDROCANNABINOL -THC)

    5.9. ESTIMATED APPROVAL TIMELINES

    5.9.1. METHODOLOGY

    5.9.2. ESTIMATED APPROVAL TIMELINES US & EX-US

    6. CANNABINOIDS OPPORTUNITIES BY AREA OF APPLICATION

    6.1. PHARMACEUTICAL INDUSTRY

    6.1.1. UNMET NEEDS AND OPPORTUNITIES

    6.1.2. EXPECTED MARKET IN 11MM

    6.2. FOOD INDUSTRY

    6.2.1. UNMET NEEDS AND OPPORTUNITIES

    6.2.2. EXPECTED MARKET IN 11MM

    6.3. COSMETIC INDUSTRY

    6.3.1. UNMET NEEDS AND OPPORTUNITIES

    6.3.2. EXPECTED MARKET IN 11MM

    7. CURRENT AND FUTURE COMPETITIVE LANDSCAPE

    7.1. COMPANIES

    7.1.1. ESTABLISHED COMPANY PROFILES WITH SWOT ANALYSIS

    7.1.1.1. GW RESEARCH LTD

    7.1.1.2. ABBVIE INC

    7.1.1.3. INSYS THERAPEUTICS

    7.1.1.4. MYLAN PHARMA

    7.1.1.5. TILRAY

    7.1.1.6. CANOPY GROWTH

    7.1.1.7. AURORA CANNABIS

    7.1.1.8. GREEN THUMB INDUSTRIES

    7.1.1.9. CRONOS GROUP

    7.1.2. EMERGING COMPANIES WITH COMPETITIVE OPPORTUNITIES

    7.1.2.1. KALYTERA THERAPEUTICS

    7.1.2.2. BOTANIX PHARMACEUTICALS

    7.1.2.3. PHYTECS

    7.1.2.4. CV SCIENCES, INC

    7.1.2.5. SERINA THERAPEUTICS, INC

    7.1.2.6. INTEC PHARMA LTD

    7.1.2.7. AXIM BIOTECHNOLOGIES

    7.1.2.8. INMED PHARMACEUTICALS INC

    7.1.2.9. CARA THERAPEUTICS (COVERED CANNABINOID RELATED INFORMATION ONLY)

    7.1.2.10. VIVACELL BIOTECHNOLOGY ESPANA SL

    7.1.2.11. CARDIOL THERAPEUTICS INC

    7.1.2.12. PIVOT PHARMACEUTICALS

    7.1.2.13. ARTELO BIOSCIENCES

    7.1.2.14. TETRA BIO-PHARMA

    7.1.2.15. NEMUS BIOSCIENCE INC

    7.1.2.16. SCYTHIAN BIOSCIENCES

    7.1.2.17. ICD PHARMA

    7.1.2.18. CANADIAN CANNABIS MEDICAL TECHNOLOGIES

    7.1.2.19. ZYNERBA PHARMACEUTICALS

    7.1.2.20. THERAPIX BIOSCIENCES

    7.1.2.21. REVIVE THERAPEUTICS

    7.1.2.22. PANAG PHARMA

    7.1.2.23. ZELDA THERAPEUTICS PTY LTD

    7.2. UNIVERSITIES AND INSTITUTES

    8. ABBREVIATIONS

List Of Tables
in Cannabinoids (CBD and THC) Drugs: Pipeline Analysis and Opportunity Assessment, H1 2020

LIST OF TABLES

TABLE 1: ECS STIMULATION ON DIFFERENT PARTS OF THE BODY

TABLE 2: AMOUNT SPENT ON MARIJUANA REASERCH, 2014-2017, US, IN $M

TABLE 3: MAJOR COLLABORATIVE AGREEMENTS INVOLVING CANNABINOID

TABLE 4: MAJOR LICENSING AGREEMENTS INVOLVING CANNABINOID

TABLE 5: MAJOR PARTNERSHIPS INVOLVING CANNABINOID

TABLE 6: MAJOR AGREEMENTS INVOLVING CANNABINOID

TABLE 7: EMA APPROVED CANNABIS DRUGS

TABLE 8: US FDA APPROVED CANNABIS DRUGS

TABLE 9: PHASE 3 MOLECULES IN THE CANNABINOID DRUG PIPELINE

TABLE 10: PHASE 2 MOLECULES IN THE CANNABINOID DRUG PIPELINE

TABLE 11: PHASE 1 MOLECULES IN THE CANNABINOID DRUG PIPELINE

TABLE 12: PRECLINICAL MOLECULES IN THE CANNABINOID DRUG PIPELINE

TABLE 13: EARLY R&D MOLECULES IN THE CANNABINOID DRUG PIPELINE

TABLE 14: HSD-UNKNOWN MOLECULES IN THE CANNABINOID DRUG PIPELINE

TABLE 15: CANNABINOID DRUG PIPELINE MOLECULES BY ORAL AS ROUTE OF ADMINISTRATION

TABLE 16: CANNABINOID DRUG PIPELINE MOLECULES BY TOPICAL AS ROUTE OF ADMINISTRATION

TABLE17: CANNABINOID DRUG PIPELINE MOLECULES BY INTRAVENOUS AS ROUTE OF ADMINISTRATION

TABLE 18: CANNABIDIOL DRUG PIPELINE MOLECULES BY TRANSDERMAL AS ROUTE OF ADMINISTRATION

TABLE 19: OTHER DIFFERENT ROUTE OF ADMINISTRATION FOR CANNABINOID DRUG PIPELINE

TABLE 20: CANNABINOID DRUG PIPELINE INDICATED FOR CANCER

TABLE 21: CANNABINOID DRUG PIPELINE INDICATED FOR CARDIOVASCULAR, METABOLICS & HEMATOLOGY

TABLE 22: CANNABINOIDDRUG PIPELINE INDICATED FOR CENTRAL NERVOUS SYSTEM

TABLE 23: CANNABINOID DRUG PIPELINE INDICATED FOR DERMATOLOGY

TABLE 24: CANNABINOID DRUG PIPELINE INDICATED FOR ENT & OPHTHALMOLOGY MARKET

TABLE 25: CANNABINOIDDRUG PIPELINE INDICATED FOR GASTROINTESTINAL MARKET

TABLE 26: CANNABINOID DRUG PIPELINE INDICATED FOR GENETIC AND RARE DISEASE MARKET

TABLE 27: CANNABINOID DRUG PIPELINE INDICATED FOR IMMUNOLOGY & INFLAMMATORY MARKET

TABLE 28: CANNABINOID DRUG PIPELINE INDICATED FOR INFECTIOUS DISEASE MARKET

TABLE 29: CANNABINOID DRUG PIPELINE INDICATED FOR RESPIRATORY MARKET

TABLE 30: CANNABINOID DRUG PIPELINE MOLECULES IN OTHER MARKET

TABLE 31: COMPANIES DEVELOPING PLANT DERIVED MOLECULES

TABLE 32: COMPANIES DEVELOPING SYNTHETIC MOLECULES

TABLE 33: COMPANIES DEVELOPING BIOSYNTHETIC MOLECULES

TABLE 34: COMPANIES DEVELOPING CBD MOLECULES

TABLE 35: COMPANIES DEVELOPING THC MOLECULES

TABLE 36: COMPANIES DEVELOPING CBD AND THC MOLECULES

TABLE 37: ESTIMATED APPROVAL TIMELINES OF PIPELINE MOLECULES

TABLE 38: GW RESEARCH PRODUCT PORTFOLIO

TABLE 39: R&D ACTIVITIES OF GW RESEARCH

TABLE 40: CONFERENCES/SEMINARS ATTENDED BY GW RESEARCH

TABLE 41: RECENT DEVELOPMENTS MADE BY GW RESEARCH

TABLE 42: SWOT ANALYSIS OF GW RESEARCH

TABLE 43: ABBVIE PRODUCT PORTFOLIO

TABLE 44: CONFERENCES/SEMINARS ATTENDED BY ABBVIE

TABLE 45: RECENT DEVELOPMENTS MADE BY ABBVIE

TABLE 46: SWOT ANALYSIS OF ABBVIE

TABLE 47: INSYS THERAPEUTICS PRODUCT PORTFOLIO

TABLE 48: R&D ACTIVITIES OF INSYS THERAPEUTICS

TABLE 49: CONFERENCES/SEMINARS ATTENDED BY INSYS THERAPEUTICS

TABLE 50: RECENT DEVELOPMENTS MADE BY INSYS THERAPEUTICS

TABLE 51: SWOT ANALYSIS OF INSYS THERAPEUTICS

TABLE 52: MYLAN PHARMA PRODUCT PORTFOLIO

TABLE 53: MYLAN PHARMA PRODUCT PIPELINE

TABLE 54: CONFERENCES/SEMINARS ATTENDED BY MYLAN PHARMA

TABLE 55: RECENT DEVELOPMENTS MADE BY MYLAN PHARMA

TABLE 56: SWOT ANALYSIS OF MYLAN PHARMA

TABLE 57: TILRAY PRODUCT PORTFOLIO

TABLE 58: CONFERENCES/SEMINARS ATTENDED BY TILRAY

TABLE 59: RECENT DEVELOPMENTS MADE BY TILRAY

TABLE 60: SWOT ANALYSIS OF TILRAY

TABLE 61: CANOPY GROWTH PRODUCT PORTFOLIO

TABLE 62: RECENT DEVELOPMENTS MADE BY CANOPY GROWTH

TABLE 63: SWOT ANALYSIS OF CANOPY GROWTH

TABLE 64: AURORA CANNABIS PRODUCT PORTFOLIO

TABLE 65: R&D ACTIVITIES OF AURORA CANNABIS

TABLE 66: RECENT DEVELOPMENTS MADE BY AURORA CANNABIS

TABLE 67: SWOT ANALYSIS OF AURORA CANNABIS

TABLE 68: GREEN THUMB INDUSTRIES PRODUCT PORTFOLIO

TABLE 69: CONFERENCES/SEMINARS ATTENDED BY GREEN THUMB INDUSTRIES

TABLE 70: RECENT DEVELOPMENTS MADE BY GREEN THUMB INDUSTRIES

TABLE 71: SWOT ANALYSIS OF GREEN THUMB INDUSTRIES

TABLE 72: CRONOS GROUP PRODUCT PORTFOLIO

TABLE 73: R&D ACTIVITIES OF CRONOS GROUP

TABLE 74: SWOT ANALYSIS OF CRONOS GROUP

TABLE 75: KALYTERA THERAPEUTICS FUTURE MILESTONES

TABLE 76: KALYTERA THERAPEUTICS RECENT DEVELOPMENTS AND MILESTONES

TABLE 77: BOTANIX PHARMACEUTICALS RECENT DEVELOPMENTS AND MILESTONES

TABLE 78: PHYTECS PRODUCT PORTFOLIO

TABLE 79: PHYTECS RECENT DEVELOPMENTS AND MILESTONES

TABLE 80: CV SCIENCES FUTURE MILESTONES

TABLE 81: CV SCIENCES RECENT DEVELOPMENTS AND MILESTONES

TABLE 82: SERINA THERAPEUTICSRECENT DEVELOPMENTS AND MILESTONES

TABLE 83: INTEC PHARMA FUTURE MILESTONES

TABLE 84: INTEC PHARMA RECENT DEVELOPMENTS AND MILESTONES

TABLE 85: AXIM BIOTECHNOLOGIES RECENT DEVELOPMENTS AND MILESTONES

TABLE 86: INMED PHARMACEUTICALS FUTURE MILESTONES

TABLE 87: INMED PHARMACEUTICALS RECENT DEVELOPMENTS AND MILESTONES

TABLE 88: VIVACELL BIOTECHNOLOGY RECENT DEVELOPMENTS AND MILESTONES

TABLE 89: CARDIOL THERAPEUTICS FUTURE MILESTONES

TABLE 90: CARDIOL THERAPEUTICS RECENT DEVELOPMENTS AND MILESTONES

TABLE 91: ARTELO BIOSCIENCES PRODUCT PORTFOLIO

TABLE 92: RECENT DEVELOPMENTS AND FUTURE MILESTONES OF ARTELO BIOSCIENCES

TABLE 93: TETRA BIO-PHARMA FUTURE MILESTONES

TABLE 94: TETRA BIO-PHARMA RECENT DEVELOPMENTS AND MILESTONES

TABLE 95: NEMUS BIOSCIENCE RECENT DEVELOPMENTS AND MILESTONES

TABLE 96: ZYNERBA PHARMACEUTICALS FUTURE MILESTONES

TABLE 97: ZYNERBA PHARMACEUTICALS RECENT DEVELOPMENTS AND MILESTONES

TABLE 98: ZELDA THERAPEUTICS FUTURE MILESTONES

TABLE 99: ZELDA THERAPEUTICS RECENT DEVELOPMENTS AND MILESTONES

TABLE 100: UNIVERSITIES AND INSTITUTES CONDUCTING RESEARCH ON CANNABINOIDS

List Of Figures, Charts and Diagrams
in Cannabinoids (CBD and THC) Drugs: Pipeline Analysis and Opportunity Assessment, H1 2020

LIST OF FIGURES

FIGURE 1: KEY PIPELINE EVENTS, 2019-2032

FIGURE 2: KEY PIPELINE EVENTS, 2019-2021

FIGURE 3: PHARMACODYNAMIC EFFECTS OF KEY CANNABINOIDS

FIGURE 4: OVERALL DEALS ACTIVITY INVOLVING CANNABINOID

FIGURE 5: GEOGRAPHY WISE BREAK UP V/S DEAL TYPE

FIGURE 6: CANNABINOID DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT

FIGURE 7: CANNABINOID DRUG PIPELINE ANALYSIS BY GEOGRAPHY

FIGURE 8: CANNABINOID DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT V/S GEOGRAPHIES

FIGURE 9: CANNABINOID DRUG PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION

FIGURE 10: CANNABINOID DRUG PIPELINE ANALYSIS BY INDICATION

FIGURE 11: GRAPHICAL VIEW OF PIPELINE MOLECULE'S STAGE OF DEVELOPMENT VS SOURCE OF ORIGIN

FIGURE 12: GRAPHICAL VIEW OF PIPELINE MOLECULE'S GEOGRAPHY VS SOURCE OF ORIGIN

FIGURE 13: PIPELINE MOLECULE'S ANALYTICS BY TYPE (CBD VS THC)

FIGURE 14: GRAPHICAL VIEW OF PIPELINE MOLECULE'S STAGE OF DEVELOPMENT VS MOLECULE TYPE

FIGURE 15: GRAPHICAL VIEW OF PIPELINE MOLECULE'S GEOGRAPHY VS MOLECULE TYPE

FIGURE 16: CANNABINOID OPPORTUNITY ASSESSMENT

FIGURE 17: TOTAL CANNABINOID MARKET, 2016 V/S 2025

FIGURE 18: PHARMACEUTICAL INDUSTRY CANNABINOID MARKET, 2016 V/S 2025

FIGURE 19: FOOD INDUSTRYCANNABINOID MARKET, 2016 V/S 2025

FIGURE 20: COSMETIC INDUSTRYCANNABINOID MARKET, 2016 V/S 2025

FIGURE 21: FINANCIAL INFORMATION OF GW RESEARCH

FIGURE 22: FINANCIAL INFORMATION OF ABBVIE

FIGURE 23: FINANCIAL INFORMATION OF INSYS THERAPEUTICS

FIGURE 24: FINANCIAL INFORMATION OF MYLAN PHARMA

FIGURE 25: FINANCIAL INFORMATION OF TILRAY

FIGURE 26: FINANCIAL INFORMATION OF CANOPY GROWTH

FIGURE 27: FINANCIAL INFORMATION OF AURORA CANNABIS

FIGURE 28: FINANCIAL INFORMATION OF GREEN THUMB INDUSTRIES

FIGURE 29: FINANCIAL INFORMATION OF CRONOS GROUP

Additional Details

Publisher

Gervano R A

Publisher Information

GervanoRA Data Services LLP is a premier provider of syndicated research reports, custom research reports, and consulting services, based in Goa. It provides Market Research And Analysis Services to its clients globally.



GDS aims to deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial views of the competitive framework, and future market trends.



At GervanoRA Data Services, we’re playing our part to help clients stay ahead of the curve. We collaboratively work with a wide range of organizations to garner valuable key insights.

Reference

270543 | GERPH503

Number of Pages

200

Report Format

PDF

Gervano R A Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Cannabinoids/Marijuana Test Volume and Sales Forecasts to 2021: US, Europe, Japan--Hospitals, Commercial Labs, POC Locations
This new report from VPGMarketResearch.com provides analysis of Cannabinoids/Marijuana testing, incl...
13 Jun 2017 by Venture Planning Group (VPG) USD $750 More Info
2017 Cannabinoids/Marijuana Test Volume and Sales Forecasts: US, Europe, Japan--Hospitals, Commercial Labs, POC Locations
This new report from VPGMarketResearch.com provides analysis of Cannabinoids/Marijuana testing, incl...
30 Mar 2017 by Venture Planning Group (VPG) USD $750 More Info
2017 Cannabinoids/Marijuana Test Volume and Sales Forecasts: US, Europe, Japan--Hospitals, Commercial Labs, POC Locations
This new report from VPGMarketResearch.com provides analysis of Cannabinoids/Marijuana testing, incl...
15 Mar 2017 by Venture Planning Group (VPG) USD $750 More Info
2017 Cannabinoids/Marijuana Test Volume and Sales Forecasts: US, Europe, Japan--Hospitals, Commercial Labs, POC Locations
This new report from VPGMarketResearch.com provides analysis of Cannabinoids/Marijuana testing, incl...
15 Mar 2017 by Venture Planning Group (VPG) USD $750 More Info
Cannabinoids/Marijuana Test Volume and Sales Forecasts: US, Europe, Japan--Hospitals, Commercial Labs, POC Locations
This new report from VPG Market Research provides analysis of Cannabinoids/Marijuana testing, includ...
29 Jul 2016 by Venture Planning Group (VPG) USD $750 More Info
Cannabinoids/Marijuana Test Volume and Sales Forecasts: US, Europe, Japan--Hospitals, Commercial Labs, POC Locations
This new report from VPG Market Research provides analysis of Cannabinoids/Marijuana testing, includ...
29 Jul 2016 by Venture Planning Group (VPG) USD $750 More Info
Antiemetic Drugs Market Analysis: By Type of Drug (5-HT3 receptor antagonists, Dopamine antagonists, Steroid-Corticosteroids, Benzodiazepines, NK1 receptor antagonist, Antihistamines, Cannabinoids, Anticholinergic); By Application– With Forecast (2016-2021)
Antiemetic drugs are those that have the ability to treat conditions such as nausea and vomitting. T...
16 Mar 2016 by USD $5,250 More Info

This report is published by Gervano R A

GervanoRA Data Services LLP is a premier provider of syndicated research reports, custom research reports, and consulting services, based in Goa. It provides Market Research And Analysis Services to its clients globally.

GDS aims to deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial views of the competitive framework, and future market trends.

At GervanoRA Data Services, we’re playing our part to help clients stay ahead of the curve. We collaboratively work with a wide range of organizations to garner valuable key insights.

Download Free Report Summary PDF

Cannabinoids (CBD and THC) Drugs: Pipeline Analysis and Opportunity Assessment, H1 2020 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...